[HTML][HTML] Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels
JN Kochenderfer, RPT Somerville, T Lu… - Journal of clinical …, 2017 - ncbi.nlm.nih.gov
JN Kochenderfer, RPT Somerville, T Lu, V Shi, A Bot, J Rossi, A Xue, SL Goff, JC Yang…
Journal of clinical oncology, 2017•ncbi.nlm.nih.govPurpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting
CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results
supporting treatment of lymphoma with CAR-19 T cells have been published. Patients with
lymphoma that is chemotherapy refractory or relapsed after autologous stem-cell
transplantation have a grim prognosis, and new treatments for these patients are clearly
needed. Chemotherapy administered before adoptive T-cell transfer has been shown to …
CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results
supporting treatment of lymphoma with CAR-19 T cells have been published. Patients with
lymphoma that is chemotherapy refractory or relapsed after autologous stem-cell
transplantation have a grim prognosis, and new treatments for these patients are clearly
needed. Chemotherapy administered before adoptive T-cell transfer has been shown to …
Abstract
Purpose
T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been published. Patients with lymphoma that is chemotherapy refractory or relapsed after autologous stem-cell transplantation have a grim prognosis, and new treatments for these patients are clearly needed. Chemotherapy administered before adoptive T-cell transfer has been shown to enhance the antimalignancy activity of adoptively transferred T cells.
ncbi.nlm.nih.gov